🔥 Hot Today in Peptide Research

🔥🔥

House bill would direct the VA to study peptides for veterans

Photo: Aziz Acharki / StockSnap (CC0) / own upload

Stars and Stripes reported on 28 September that Rep. Nancy Mace has introduced the PEPTIDES for Veterans Act, which would direct the Department of Veterans Affairs to run an 18-month study of the safety and efficacy of peptides for veterans with service-connected conditions. According to the report, the VA would first review current peptide regulations and give Congress its official definitions of "peptide" and "peptide-based therapy", and a five-year pilot would follow only if the initial findings are positive. The bill has been referred to the House Veterans' Affairs health subcommittee.

For research-community awareness only. Not legal advice.

BioLabs Research has no affiliation with, and no endorsement from, any person named. Source: Stars and Stripes

🔥

Comment window closes on FDA's revised generic peptide guidances

Photo: FreePhotos / StockSnap (CC0) / own upload

The Federal Register notice published on 29 July set 28 September 2026 as the deadline for comments on FDA's revised draft product-specific guidances for generic peptide drugs. These guidances set out how generic manufacturers should show bioequivalence to an approved reference product, and the notice lists active ingredients of several peptide drugs, including incretin-class compounds, teriparatide, glucagon and calcitonin salmon. According to the notice, FDA considers comments received by the deadline before it begins work on the final versions.

For research-community awareness only. Not legal advice.